Extremely important negative changes in investment behavior have recently occurred for Nektar Therapeutics (NASDAQ: NKTR): negative upside/downside volume developed, and the stock fell on very heavy volume.
Nektar Therapeutics (NASDAQ: NKTR). Important negative changes in fundamentals have recently occurred: significant quarterly sales deceleration occurred, and significant quarterly earnings deceleration occurred.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to fall short of the cost of capital, NKTR is expected to continue to be a major Value Eraser.
Nektar Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Nektar Therapeutics has a poor Appreciation Score of 20 and a very low Power Rating of 14, leading to the Lowest Value Trend Rating.
Recent Price Action
On 8/14/19, Nektar Therapeutics (NASDAQ: NKTR) stock declined modestly by -0.7%, closing at $18.72. Moreover, trading volume in this decline was exceptionally high at 206% of normal. The stock has declined -34.9% during the last week and has been weak relative to the market over the last nine months.